Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.
Andre H. Goy, MD, MS
Advertisement
Articles by Andre H. Goy, MD, MS
Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.
Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).
Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).
Advertisement
Latest Updated Articles
Dr. Goy on the Utility of Novel Agents in MCLFebruary 3rd 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma
2
Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL
3
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
4
Breaking Treatment Barriers: Therapy for Advanced (Metastatic) EGFR-Mutated Non-Small Cell Lung Cancer After Targeted Therapy and Chemotherapy
5